Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Equity Securities (Details Narrative)

Equity Securities (Details Narrative) - USD ($)		1 Months Ended						12 Months Ended
Equity Securities (Details Narrative) - USD ($)	Jan. 12, 2024	Nov. 30, 2023	Nov. 20, 2023	May 26, 2023	Mar. 31, 2023	Mar. 20, 2023	Apr. 25, 2022	Dec. 31, 2023	Dec. 31, 2022	Jul. 11, 2022
Warrants outstanding								8,358,697	437,102
Warrants to purchase shares of Common Stock			3,472,095
Warrant reduced description								from $21.20 to $2.82 per share upon closing of the March 2023 Offering
Preferred stock authorized								10,000,000	10,000,000
Preferred stock shares, issued								0	0
Preferred stock shares, outstanding								0	0
Net cash proceeds from PIPE				$ 1,500,000
Common stock shares, authorized								250,000,000	250,000,000	90,000,000
Received net cash proceeds	$ 2,000,000.0
Offering expenses	$ 300,000
Underwriters discounts and offering expenses				$ 300,000
Preferred stock par value								$ 0.0001
Exercise price per share			$ 2.82
Reduced exercise price			$ 0.6511
Description of abeyance shares								the Holder left 2,730,000 shares in abeyance at the Company’s transfer agent to be delivered to the Holder at their request. The 2,730,000 shares held in abeyance were delivered to the Holder on January 8, 2024. Accordingly, as of December 31, 2023, 2,730,000 shares were held in abeyance, have not been issued and are not outstanding
Warrants Member
Warrants outstanding								0
Common Stock and Preferred Stock
Exercise price per share							$ 0.0001
Warrants to purchase shares of Common Stock							235,849
Net cash proceeds						$ 4,200,000	$ 4,300,000
Underwriters' discounts and offering expenses						$ 800,000	$ 700,000
Common stock, shares sold				458,555		85,000	56,161
Pre funded							179,687
Pre-funded warrants to purchase shares of Common Stock							179,687
Warrants sold to purchase one share of common stock, Exercise price							$ 21.20
PIPE Common Warrants
Warrants outstanding								0	235,849
Exercise price								$ 2.82
PIPE Common Warrants \| May 2023
Warrants outstanding								800,877	0
Exercise price				$ 2.16				$ 2.16
Offering price				$ 2.285
Warrant units to purchase stocks				800,877
Warrants sold to purchase one share of common stock				800,877
Warrant [Member]
Warrants outstanding								8,358,697
Fair value, per share								$ 0.61
Intrinsic value of warrants outstanding								$ 0
Warrants to purchase shares of Common Stock		3,472,095
Warrants, expire date								April 2022
Exercise price per share		$ 0.6511
Net cash proceeds		$ 2,000,000.0
Equity issuance cost		$ 3,000,000.0			$ 100,000
Class B Common Units \| Warrants Member
Exercise price per share						$ 2.82
Fair value Exercise price per share						$ 3.09
Warrants to purchase shares of Common Stock						1,618,123
Common and Pre-Funded Warrants [Member]
Warrant units to purchase stocks				342,322
Warrants to purchase shares of Common Stock						1,618,123
Pre-funded warrants to purchase shares of Common Stock						1,533,123
Warrants sold to purchase one share of common stock				342,322
Exercise price				$ 0.0001		$ 0.0001
PIPE \| Warrants Member
Warrant units to purchase stocks						1,618,123
Warrants sold to purchase one share of common stock						1,618,123
Exercisable warrant outstanding						1,533,123
Exercise price						$ 2.82
Series A Common Stock Warrants [Member]
Warrants to purchase shares of Common Stock			3,707,944
Exchange Series A Common Warrants to Series B Common Warrants		3,236,246
Exercise price per share		$ 0.6511
Series B Common Stock Warrants [Member]
Warrants to purchase shares of Common Stock			3,236,246